secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-131786
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports positive Phase 2 FREEDOM2 data for PGN-EDODM1 in DM1; splicing correction 22.9% ex-outlier
--------------------------------------------------------------------------------

- 5 mg/kg cohort (n=8): mean splicing correction 7.3% overall, 22.9% excluding outlier; placebo 6.8%.
- No serious adverse events; all TEAEs mild/moderate; nausea most common; no renal toxicity.
- Middle finger vHOT showed improvement trend vs placebo worsening; returned to baseline at Week 16.
- 10 mg/kg cohort >50% enrolled; data expected 2H 2026; cash sufficient into 2H 2027.
- Mean muscle PGN-EDODM1 concentration 158 ng/g in 5 of 6 treated patients (one pending).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312526131786/0001193125-26-131786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312526131786/pepg-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-131786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer